Positive Report for Charles River Labs (CRL) from Evercore ISI
Charles River Labs (CRL – Research Report) received a Buy rating and price target from Evercore ISI analyst Elizabeth Anderson CFA yesterday.
Protect Your Portfolio Against Market Uncertainty
Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
According to TipRanks, Anderson CFA is an analyst with an average return of -6.6% and a 42.49% success rate. Anderson CFA covers the Healthcare sector, focusing on stocks such as Icon, Charles River Labs, and CVS Health.
Currently, the analyst consensus on Charles River Labs is a Hold with an average price target of $152.50.
Based on Charles River Labs' latest earnings release for the quarter ending December 28, the company reported a quarterly revenue of $1 billion and a GAAP net loss of $213.41 million. In comparison, last year the company earned a revenue of $1.01 billion and had a net profit of $187.08 million
Based on the recent corporate insider activity of 59 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CRL in relation to earlier this year. Most recently, in February 2025, Birgit Girshick, the Corporate Executive VP & COO of CRL bought 1,514.00 shares for a total of $249,249.82.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
CRL Q1 Earnings Call: Regulatory Changes and Market Stabilization Shape Outlook
Lab services company Charles River Laboratories (NYSE:CRL) reported Q1 CY2025 results exceeding the market's revenue expectations , but sales fell by 2.7% year on year to $984.2 million. Its non-GAAP profit of $2.34 per share was 12.8% above analysts' consensus estimates. Is now the time to buy CRL? Find out in our full research report (it's free). Revenue: $984.2 million vs analyst estimates of $941.3 million (2.7% year-on-year decline, 4.6% beat) Adjusted EPS: $2.34 vs analyst estimates of $2.07 (12.8% beat) Management raised its full-year Adjusted EPS guidance to $9.55 at the midpoint, a 2.1% increase Operating Margin: 7.6%, down from 12.5% in the same quarter last year Organic Revenue fell 1.8% year on year (-3.3% in the same quarter last year) Market Capitalization: $7.42 billion Charles River Laboratories' first quarter results reflected a period of stabilization amid shifting regulatory and market dynamics. Management attributed performance to stronger-than-expected demand in the Drug Discovery and Safety Assessment (DSA) segment, particularly from global biopharmaceutical clients seeking quicker study starts. CEO Jim Foster emphasized the company's ongoing adaptation to regulatory developments, notably the FDA's push for New Approach Methods (NAMs) to reduce animal testing in preclinical research. Segment performance was mixed, with resilience in research models and manufacturing partially offset by declines in certain specialty areas. The leadership team acknowledged that industry headwinds, such as government funding cuts and persistent uncertainties in biotech funding, continue to weigh on near-term visibility. CFO Flavia Pease credited cost-saving initiatives and improved study mix for supporting operating margins despite the revenue decline. Looking ahead, Charles River Laboratories' outlook is shaped by cautious optimism regarding market stabilization and the gradual adoption of alternative testing methods. Management raised its full-year adjusted EPS guidance, citing improved DSA bookings and a more favorable study mix, but remains wary of potential headwinds. CEO Jim Foster explained, 'We are modestly increasing our full-year revenue guidance for the DSA segment based on improved bookings, though we are not assuming this trend will persist into the second half.' The company is closely monitoring regulatory changes, particularly the FDA's evolving stance on NAMs, as well as broader factors such as NIH funding and tariffs. Strategic investments in non-animal platforms and continued cost discipline are expected to be key contributors to future performance. Management linked the quarter's outperformance to a rebound in DSA bookings, cost savings from restructuring, and incremental progress in alternative testing methods. The company also highlighted the impact of regulatory changes and evolving client demand on its business mix. DSA bookings rebound: The DSA segment saw its net book-to-bill ratio rise above 1x for the first time in over two years, driven by improved bookings from global biopharma clients and fewer cancellations across all customer segments. Management noted that much of this activity was due to studies with faster start dates, reflecting a shift toward shorter-term project commitments. NAMs and regulatory alignment: CEO Jim Foster addressed the FDA's recent push towards New Approach Methods (NAMs), which aim to reduce animal testing in drug development. While acknowledging the gradual nature of this shift, management emphasized Charles River Laboratories' investments in NAMs platforms, such as organ-on-a-chip and in silico (computer-based) modeling, and reported approximately $200 million in annual DSA revenue from NAMs-related services. Segment-specific headwinds: The Research Models and Services (RMS) segment experienced a modest decline, primarily attributed to the timing of non-human primate (NHP) shipments in China and weaker Cell Solutions revenue. Academic and government clients presented a potential risk due to proposed NIH budget cuts, though no immediate impact was observed in the quarter. Manufacturing dynamics: Manufacturing revenue was flat year over year, with growth in Microbial Solutions offset by lower commercial revenue in the Cell and Gene Therapy CDMO business. Biologics Testing volumes started the year slowly, but management expressed confidence in a rebound as the year progresses, citing strong booking activity. Cost management and board changes: Ongoing restructuring and cost-saving initiatives contributed to operating margin stability. The company announced new board members and a strategic review in collaboration with Elliott Investment Management, aiming to identify value creation opportunities and optimize capital allocation. Management's outlook for the remainder of the year hinges on sustained DSA momentum, regulatory adaptation, and prudent cost controls, with caution around funding and regulatory shifts. Evolving regulatory landscape: The FDA's initiative to accelerate NAMs adoption will influence both client demand and Charles River Laboratories' service mix. Management believes broader adoption of NAMs will be gradual and expects hybrid models (combining NAMs with animal studies) to become more common, especially in monoclonal antibody research. Market stabilization and client mix: Leadership anticipates continued stabilization in demand from small and midsized biotech clients, despite ongoing funding challenges. However, the company remains cautious about potential pullbacks in academic and government spending if NIH budget cuts materialize later in the year or in 2026. Cost discipline and operational efficiency: Continued focus on cost-saving measures and restructuring is expected to help maintain margins. Management projects durable savings from recent initiatives while balancing investment in new capabilities and preparation for possible market headwinds. In the coming quarters, the StockStory team will track (1) whether DSA bookings and net book-to-bill ratios remain above 1x, (2) the pace of NAMs adoption and its impact on both revenue mix and client study designs, and (3) any signs of reduced spending from academic and government clients if NIH funding changes take effect. Additional attention will be given to the outcomes of the board's strategic review and progress in Manufacturing segment recovery. Charles River Laboratories currently trades at a forward P/E ratio of 15.8×. Should you double down or take your chips? The answer lies in our full research report (it's free). Market indices reached historic highs following Donald Trump's presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth. While this has caused many investors to adopt a "fearful" wait-and-see approach, we're leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today. Sign in to access your portfolio
Yahoo
8 hours ago
- Yahoo
Mixed options sentiment in CrowdStrike Holdings with shares up 0.12%
Mixed options sentiment in CrowdStrike Holdings (CRWD), with shares up 55c, or 0.12%, near $464.94. Options volume relatively light with 5050 contracts traded and calls leading puts for a put/call ratio of 0.48, compared to a typical level near 0.76. Implied volatility (IV30) dropped 0.2 near 35.4,in the bottom quartile of the past year, suggesting an expected daily move of $10.37. Put-call skew steepened, indicating increased demand for downside protection, following a downgrade to In Line at Evercore ISI. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders' Hot Stocks on TipRanks >> Read More on CRWD: Disclaimer & DisclosureReport an Issue Trump Trade: U.S., China representatives to meet about trade Cardinal Health, Dollar General, Snowflake, Constellation, and CrowdStrike: Trending by Analysts Trump signs Executive Order intended to 'strengthen the nation's cybersecurity' U.S. Layoffs Surge despite Strong Jobs Data as Major Corporations Make Cuts U.S. payrolls rise 139,000, Broadcom reports Q2 beat: Morning Buzz Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
8 hours ago
- Yahoo
Trump Trade: RFK Jr. removes members of vaccine-advising CDC panel
Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President Donald Trump with this daily recap compiled by The Fly: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter VACCINE ADVISORY COMMITTEE: In an opinion article published by The Wall Street Journal, Robert F. Kennedy Jr. stated, 'Vaccines have become a divisive issue in American politics, but there is one thing all parties can agree on: The U.S. faces a crisis of public trust. Whether toward health agencies, pharmaceutical companies or vaccines themselves, public confidence is waning… That is why, under my direction, the U.S. Department of Health and Human Services is putting the restoration of public trust above any pro- or antivaccine agenda… Today, we are taking a bold step in restoring public trust by totally reconstituting the Advisory Committee for Immunization Practices. We are retiring the 17 current members of the committee, some of whom were last-minute appointees of the Biden administration. Without removing the current members, the current Trump administration would not have been able to appoint a majority of new members until 2028… A clean sweep is needed to re-establish public confidence in vaccine science.' DRUG PRICES: Pfizer (PFE) and other drugmakers met with the Trump administration to discuss lowering U.S. drug prices but no commitments have been made, Pfizer CEO Albert Bourla said on Monday at the Goldman Sachs Healthcare Conference. Boula said the meetings 'were cordial,' but they were not 'digging into the substance yet,' adding that 'it is just trying to understand high-level ideas and no commitments. So what could be the outcomes of something like that? It could be from nothing to very big.' TRUMP WISHES MUSK WELL: While speaking to reporters from the White House, President Trump said that he wishes Tesla (TSLA) CEO Elon Musk 'well' and downplayed a dispute with the former DOGE advisor. LIVE MUSIC VENUES: Live Nation (LYV) CEO Michael Rapino told Fox News Digital that after President Donald Trump's March executive order targeting ticket scalpers and strengthening protection for artists and their fans that the company is investing $1B to build new and revitalized live music venues in an effort to bring more big shows to smaller cities. 'Our mission is simple: help artists deliver more unforgettable live experiences – and in doing so, create jobs, revive cities, and lift up communities we touch,' Live Nation's Rapino is quoted as having told Fox News. BENEFICIARY OF ADDITIONAL TARIFFS: Raymond James says Market Perform-rated Whirlpool (WHR) is a possible incremental beneficiary of additional tariffs under Section 232 in the near future, though the ultimate policy remains unclear. Just last week, Trump increased section 232 rates on both steel and aluminum to 50% from 25% prior. Thus, the most recent developments seem to point to a redux of the net negative outcome of the first Trump administration, the firm notes. Trump's executive order last week increasing the 232 rates also amended the list of 'derivative products' included in the policy. The final lists published in the Federal Register continue to only include gas ranges, though a few aluminum parts used in appliances were also added. However, Raymond James points out that a list sent out by U.S. Customs on June 4 did include many major appliance categories. Subsequently, this morning, U.S. Customs subsequently sent out a new list, which matched today's Federal Register. It is unclear to the firm whether the June 4th list was simply a clerical error or a sign of things to come. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today's best-performing stocks on TipRanks >> Read More on JNJ: Disclaimer & DisclosureReport an Issue Deutsche Bank Sounds Alarm on Intuitive Surgical Stock (ISRG) with a Rare 'Sell' Rating RFK Jr. reconstituting vaccine advisory committee, retiring 17 current members RFK Jr. removes members of vaccine-advising CDC panel, CNBC reports Vaccine opponent hired by RFK Jr. searches CDC record for autism link, WSJ says Cautious Hold Rating for Johnson & Johnson Amid Promising Oncology Advances and Competitive Challenges Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
